A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist, Mark M Awad, Geoffrey I Shapiro, Miyako Satouchi, Toyoaki Hida, Hidetoshi Hayashi, Danielle A Murphy, Sherry C Wang, Sherry Li, Tiziana Usari, Keith D Wilner, Paul K Paik. Nat Med 2020
Times Cited: 100




List of shared articles



Times cited

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
2

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Aaron C Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel S W Tan. Lung Cancer (Auckl) 2021
0

MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies.
Matthew Lee, Prantesh Jain, Feng Wang, Patrick C Ma, Alain Borczuk, Balazs Halmos. Expert Opin Ther Targets 2021
0

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0


HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence.
Jianjiang Fu, Xiaorui Su, Zhihua Li, Ling Deng, Xiawei Liu, Xuancheng Feng, Juan Peng. Oncogene 2021
1

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
0

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
41

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Kohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, Tateaki Naito, Nobuaki Matsubara, Morihiro Watanabe, Barbara Sarholz, Andreas Johne, Toshihiko Doi. Jpn J Clin Oncol 2020
9


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

Molecular therapeutic targets in non-small cell lung cancer.
Kamya Sankar, Shirish M Gadgeel, Angel Qin. Expert Rev Anticancer Ther 2020
8

Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
3

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
114

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7

MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study.
Xue-Wen Liu, Xin-Ru Chen, Yu-Ming Rong, Ning Lyu, Chun-Wei Xu, Fang Wang, Wen-Yong Sun, San-Gao Fang, Jing-Ping Yuan, Hui-Juan Wang,[...]. Transl Oncol 2020
3

Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Liling Huang, Shiyu Jiang, Yuankai Shi. J Hematol Oncol 2020
24